339 related articles for article (PubMed ID: 37485307)
1. Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers.
Parisi A; Rossi F; De Filippis C; Paoloni F; Felicetti C; Mammarella A; Pecci F; Lupi A; Berardi R
Onco Targets Ther; 2023; 16():585-613. PubMed ID: 37485307
[TBL] [Abstract][Full Text] [Related]
2. Repositioning PARP inhibitors in the treatment of thoracic malignancies.
Passiglia F; Reale ML; Cetoretta V; Parlagreco E; Jacobs F; Listì A; Righi L; Bironzo P; Novello S; Scagliotti GV
Cancer Treat Rev; 2021 Sep; 99():102256. PubMed ID: 34261032
[TBL] [Abstract][Full Text] [Related]
3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Harrision D; Gravells P; Thompson R; Bryant HE
Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Comen EA; Robson M
Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
Front Oncol; 2021; 11():745981. PubMed ID: 34778062
[TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
11. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Reinbolt RE; Hays JL
Front Oncol; 2013 Oct; 3():237. PubMed ID: 24098868
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
13. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
[TBL] [Abstract][Full Text] [Related]
14. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on PARP Inhibitor Combinations for Ovarian Cancer.
Bonadio RC; Estevez-Diz MDP
Front Oncol; 2021; 11():754524. PubMed ID: 34976801
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
Musacchio L; Caruso G; Pisano C; Cecere SC; Di Napoli M; Attademo L; Tambaro R; Russo D; Califano D; Palaia I; Muzii L; Benedetti Panici P; Pignata S
Cancer Manag Res; 2020; 12():6123-6135. PubMed ID: 32801862
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
Keung MYT; Wu Y; Vadgama JV
J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30934991
[TBL] [Abstract][Full Text] [Related]
20. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
